ATYR PHARMA, INC. (ATYR) Return on equity 2019–2025
ATYR PHARMA, INC. (ATYR) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-109.8%FY2025 · since FY2019: -76.6% → -109.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -109.8% | -18.4 pp |
| FY2024 | -91.4% | -35.9 pp |
| FY2023 | -55.6% | +7.9 pp |
| FY2022 | -63.4% | -32.5 pp |
| FY2021 | -30.9% | +20.4 pp |
| FY2020 | -51.3% | +25.3 pp |
| FY2019 | -76.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice